RxDoctor Payments Data

Chakravarthy Reddy, MD

Pulmonary Disease · Salt Lake City, UTNPI 1508962176

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (37.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Intuitive Surgical at 35.8% of the total. Reporting peaked in 2020 at $22,129 and has fallen 77.7% since, to $4,940 in 2025. Among pulmonary disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,674in general payments, 2019–2025

Across 131 payments — averaging $623.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$29K
  • Bard Peripheral Vascular, Inc.$21K
  • Boston Scientific$17K
  • Merit Medical Systems Inc$14K
  • Pentax Of America, Inc.$500
  • Johnson & Johnson$103
  • plus $215 from 5 others
$13,191in research payments, 2019–2025

Across 3 payments — averaging $4397.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • BD$9K
  • Spiration, Inc.$4K

What the payments were for

  • Consulting fees$30,39037%
  • Speaking & faculty fees$25,17031%
  • Travel & lodging$23,22628%
  • Food & beverage$2,8744%
  • Gifts$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,674 in reported general payments places this provider in the 95th percentile of 101 pulmonary disease providers in Utah.

See all pulmonary disease providers in Utah

Medicare billing

Part B allowed, 2024
$84,980
Medicare patients
237
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$19,069
EliquisApixaban29$9,666
Clobetasol Propionate19$3,452
Levetiracetam33$1,973
Meropenem29$1,819
Scopolamine23$1,773
Gabapentin15$1,676
Sodium Chloride0.9 % Sodium Chloride84$1,649
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam16$1,192
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate26$1,183
Baclofen28$982
Bethanechol Chloride14$836
Vancomycin Hcl24$737
Omeprazole90$616
Potassium Chloride12$382

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →